In order to override these resistance mechanisms, higher doses of imatinib and combination therapy with other agents have been used with some efficacy. [29–31] However, these strategies are limited in ...
Small molecule kinase inhibitors of BCR-ABL in chronic myeloid leukemia (CML) and of FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in acute myeloid leukemia (AML) have been ...
The aim of this study was to identify genetic and protein expression/phosphorylation changes associated with acquired BCR–ABL1 kinase-independent resistance. Using reverse-phase protein arrays, we ...
Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial This is ...
DUBLIN--(BUSINESS WIRE)--The "Drug analysis: asciminib" drug pipelines has been added to ResearchAndMarkets.com's offering. Asciminib (Novartis) is a BCR-ABL-targeted tyrosine kinase inhibitor (TKI) ...
Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia (CML) patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy ...
SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, ...
SUZHOU, China and ROCKVILLE, Md., Nov. 14, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results